MedTrace Logo

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

NCT04672824 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-02-06

No results posted yet for this study

Summary

Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years

Conditions

  • RVF
  • Rift Valley Fever

Interventions

BIOLOGICAL

ChAdOx1 RVF

Single dose ChAdOx1 vectored vaccine

OTHER

Saline

0.5ml saline placebo

Sponsors & Collaborators

  • MRC/UVRI and LSHTM Uganda Research Unit

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Pontiano Kaleebu, PhD · MRC/UVRI and LSHTM Uganda Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04672824 on ClinicalTrials.gov